Russian Registry of Patients With nAMD
Condition(s):Neovascular Age-Related Macular DegenerationLast Updated:January 19, 2023Terminated
Hide Studies Not Open or Pending
Condition(s):Neovascular Age-Related Macular DegenerationLast Updated:January 19, 2023Terminated
Condition(s):Macular DegenerationLast Updated:December 5, 2019Completed
Condition(s):Neovascular Age-related Macular Degeneration (nAMD)Last Updated:February 9, 2024Completed
Condition(s):Neovascular Age-related Macular Degeneration (nAMD)Last Updated:August 21, 2023Active, not recruiting
Condition(s):To Evaluate the Safety and Tolerability of Intravitreal Injection of LX109 in Patients With nAMDLast Updated:September 5, 2023Not yet recruiting
Condition(s):Neovascular Age-related Macular DegenerationLast Updated:February 23, 2023Terminated
Condition(s):Neovascular Age-related Macular DegenerationLast Updated:December 21, 2023Completed
Condition(s):Central Serous Chorioretinopathy; Age Related Macular Degeneration; Idiopathic Poplypoidal Choroidal VasculopathyLast Updated:January 28, 2021Unknown status
Condition(s):Neovascular Age-Related Macular Degeneration (nAMD)Last Updated:May 22, 2023Recruiting
Condition(s):Neovascular Age-related Macular Degeneration(nAMD)Last Updated:November 13, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.